Myriad Genetics (MYGN) Treasury Shares (2014 - 2026)

Myriad Genetics has disclosed Treasury Shares across 13 years of filings, most recently posting $8.9 million for Q1 2026.

• In Q1 2026, Treasury Shares rose 74.51% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (up 74.51% YoY), while the FY2025 annual figure was $7.1 million, up 33.96% from the prior year.
• Treasury Shares grew to $8.9 million in Q1 2026, from $7.1 million in the prior quarter.
• Over the last five years, Treasury Shares for MYGN reached as high as $8.9 million in Q1 2026 and fell as low as $3.7 million in Q3 2022.
• The 5-year median for Treasury Shares is $5.1 million (2025), against an average of $5.4 million.
• Annual changes were most pronounced in 2025 — Treasury Shares decreased 8.93% — and 2026, when it soared 74.51%.
• A 5-year view of Treasury Shares shows it stood at $3.7 million in 2022, then gained by 18.92% to $4.4 million in 2023, then climbed by 20.45% to $5.3 million in 2024, then surged by 33.96% to $7.1 million in 2025, then rose by 25.35% to $8.9 million in 2026.
• According to Business Quant data, Treasury Shares over the past three periods registered $8.9 million, $7.1 million, and $7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.